Adhera Therapeutics Inc (ATRX)
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson’s disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
Sector: Biotechnology
Industry: Biotechnology
Adhera Therapeutics Inc
- Not computed yet: no FINRA short interest has been matched to this float.
- 110
- 1.00
Float 6.70M · FMP free float
The cost to borrow ATRX shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- No fails on record for 16–31 Oct 2026.
No price or settlement history available to chart.
FINRA publishes no off-exchange short volume for this symbol.
FINRA's weekly alternative trading system (dark pool) volume for ATRX: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.